Erika Carmel Ltd (BCUR) - Net Assets
Based on the latest financial reports, Erika Carmel Ltd (BCUR) has net assets worth ILA13.40 Million ILA (≈ $35.92K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA31.51 Million ≈ $84.49K USD) and total liabilities (ILA18.11 Million ≈ $48.56K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Erika Carmel Ltd (BCUR) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA13.40 Million |
| % of Total Assets | 42.52% |
| Annual Growth Rate | 37.06% |
| 5-Year Change | 67.64% |
| 10-Year Change | N/A |
| Growth Volatility | 358.64 |
Erika Carmel Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Erika Carmel Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Erika Carmel Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Erika Carmel Ltd (2019–2024)
The table below shows the annual net assets of Erika Carmel Ltd from 2019 to 2024. For live valuation and market cap data, see how much is Erika Carmel Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA15.04 Million ≈ $40.31K |
-36.62% |
| 2023-12-31 | ILA23.73 Million ≈ $63.61K |
-44.39% |
| 2022-12-31 | ILA42.67 Million ≈ $114.39K |
-51.55% |
| 2021-12-31 | ILA88.06 Million ≈ $236.09K |
+881.74% |
| 2020-12-31 | ILA8.97 Million ≈ $24.05K |
+188.70% |
| 2019-12-31 | ILA3.11 Million ≈ $8.33K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Erika Carmel Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7881800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA1.04 Million | 6.93% |
| Other Comprehensive Income | ILA4.78 Million | 31.82% |
| Other Components | ILA88.10 Million | 585.86% |
| Total Equity | ILA15.04 Million | 100.00% |
Erika Carmel Ltd Competitors by Market Cap
The table below lists competitors of Erika Carmel Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
iSpecimen Inc
NASDAQ:ISPC
|
$4.70 Million |
|
THREED CAPITAL INC.
F:B5K3
|
$4.70 Million |
|
Blaize Holdings, Inc. Warrants
NASDAQ:BZAIW
|
$4.70 Million |
|
Baillie Gifford Shin Nippon PLC
LSE:BGS
|
$4.70 Million |
|
Braster S.A.
WAR:BRA
|
$4.69 Million |
|
MAST ENERGY DEV. LS -001
F:97D
|
$4.69 Million |
|
Xcel Brands Inc
NASDAQ:XELB
|
$4.69 Million |
|
OMG Group Ltd
AU:OMG
|
$4.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Erika Carmel Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,727,000 to 15,037,000, a change of -8,690,000 (-36.6%).
- Net loss of 9,470,000 reduced equity.
- Other comprehensive income increased equity by 729,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-9.47 Million | -62.98% |
| Other Comprehensive Income | ILA729.00K | +4.85% |
| Other Changes | ILA51.00K | +0.34% |
| Total Change | ILA- | -36.62% |
Book Value vs Market Value Analysis
This analysis compares Erika Carmel Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 116.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 559.86x to 116.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ILA0.03 | ILA16.80 | x |
| 2020-12-31 | ILA0.09 | ILA16.80 | x |
| 2021-12-31 | ILA0.86 | ILA16.80 | x |
| 2022-12-31 | ILA0.41 | ILA16.80 | x |
| 2023-12-31 | ILA0.23 | ILA16.80 | x |
| 2024-12-31 | ILA0.14 | ILA16.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Erika Carmel Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.95%
- • Asset Turnover: 1.09x
- • Equity Multiplier: 2.31x
- Recent ROE (-62.98%) is below the historical average (-5.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 75.41% | 4.61% | 1.95x | 8.39x | ILA2.03 Million |
| 2020 | 138.94% | 14.53% | 1.80x | 5.32x | ILA11.57 Million |
| 2021 | -24.76% | -22.52% | 0.77x | 1.42x | ILA-30.61 Million |
| 2022 | -76.32% | -64.71% | 0.74x | 1.60x | ILA-36.83 Million |
| 2023 | -81.01% | -64.32% | 0.64x | 1.98x | ILA-21.59 Million |
| 2024 | -62.98% | -24.95% | 1.09x | 2.31x | ILA-10.97 Million |
Industry Comparison
This section compares Erika Carmel Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $107,045,000
- Average return on equity (ROE) among peers: -39.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Erika Carmel Ltd (BCUR) | ILA13.40 Million | 75.41% | 1.35x | $4.69 Million |
| Allmed Solutions Ltd (ALMD) | $30.22 Million | -165.46% | 0.44x | $8.53 Million |
| Bio-View Ltd (BIOV) | $18.18 Million | 11.59% | 0.71x | $4.83 Million |
| Brainsway Ltd (BWAY) | $57.32 Million | -11.27% | 0.32x | $463.07 Million |
| Erech Finance Cahalacha Ltd (EFNC) | $28.37 Million | -88.27% | 1.44x | $1.74 Million |
| Epitomee Medical Ltd (EPIT) | $39.45 Million | -39.02% | 0.40x | $62.09 Million |
| Erika Carmel-Tech Ltd (ERKA) | $88.06 Million | -24.76% | 0.42x | $5.82 Million |
| Human Xtensions Ltd (HUMX) | $104.53 Million | -51.30% | 0.15x | $2.12 Million |
| Ilex Medical (ILX) | $443.54 Million | 27.20% | 0.76x | $141.31 Million |
| Pulsenmore Ltd (PULS) | $153.73 Million | -16.67% | 0.09x | $22.89 Million |
About Erika Carmel Ltd
Erika B-Cure Laser Ltd develops, manufactures, markets, distributes, and sells the B-Cure laser products in Israel and internationally. It offers B-Cure Laser Classic, a home medical device for the treatment of pain, orthopedic problems, dermatology, analgesia, inflammation, and wound healing; and B-Cure Laser Pro, a device for the treatment of acute and chronic problems, such as orthopedic probl… Read more